MODULE 1: Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Dr Wakelee

• Design, eligibility criteria and key efficacy and safety findings from the Phase III IMpower010 trial evaluating atezolizumab versus best supportive care after adjuvant chemotherapy for completely resected NSCLC
• Recent FDA approval of adjuvant atezolizumab for patients with Stage II to Stage IIIA NSCLC and PD-L1 expression ≥1%; optimal integration into practice
• Recently presented data from the Phase III PEARLS/KEYNOTE-091 study of pembrolizumab as adjuvant therapy for Stage IB to IIIA NSCLC
• Key findings from the Phase III CheckMate 816 trial evaluating nivolumab in combination with chemotherapy as neoadjuvant therapy for resectable NSCLC; recent FDA approval of neoadjuvant nivolumab and appropriate identification of candidates for this strategy
• Long-term efficacy and safety findings, including 5-year overall survival data, from the Phase III PACIFIC trial evaluating consolidation durvalumab after chemoradiation therapy for unresectable Stage III NSCLC; patient selection for and practical implementation of consolidation durvalumab
• Mechanisms of antitumor activity of oleclumab and monalizumab; efficacy and safety observed with durvalumab in combination with oleclumab or monalizumab in the randomized Phase II COAST study
• Other data sets and ongoing clinical trials with immune checkpoint inhibitors for nonmetastatic NSCLC

MODULE 2: Contemporary Treatment for Localized and Metastatic NSCLC with EGFR Mutations — Dr Yu

• Principal efficacy and safety findings, including rates of central nervous system (CNS) disease recurrence, from the Phase III ADAURA trial evaluating adjuvant osimertinib for localized NSCLC with an EGFR mutation
• Recent FDA approval of adjuvant osimertinib; patient selection and optimal incorporation into clinical care
• Optimal first-line treatment for patients with metastatic NSCLC and EGFR tumor mutations, including those with CNS metastases
• Mechanisms of resistance to osimertinib; published findings with and ongoing evaluation of EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib and lazertinib combined with other agents for patients who experience disease progression on first-line osimertinib
• Available data with and ongoing evaluation of the novel HER3-directed antibody-drug conjugate patritumab deruxtecan for metastatic EGFR TKI-resistant NSCLC
• Efficacy and safety findings supporting the recent FDA accelerated approvals of amivantamab and mobocertinib for patients with metastatic NSCLC and EGFR exon 20 insertion mutations

MODULE 3: Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions — Dr Gainor

• Key findings with novel ALK inhibitors (eg, alectinib, brigatinib, lorlatinib) as first-line therapy for patients with NSCLC with ALK rearrangements; clinical factors in the choice of up-front treatment
• Indications for repeat biomarker testing for patients with progressive NSCLC with ALK rearrangements; selection of therapy for patients who experience disease progression on first-line ALK inhibition
• Efficacy and safety results with entrectinib for NSCLC with ROS1 fusions; appropriate integration into clinical practice, including for patients with CNS involvement
• Published data with and ongoing trials of other “next-generation” ROS1 inhibitors (eg, repotrectinib, lorlatinib)
• Available safety and efficacy results with selpercatinib or pralsetinib for RET fusion-driven advanced NSCLC; current role in clinical practice
• Design, eligibility and key endpoints of Phase III studies comparing first-line selpercatinib or pralsetinib to chemotherapy with or without pembrolizumab for patients with treatment-naïve NSCLC with RET fusions

MODULE 4: Targeting Alterations in MET, HER2, KRAS and Other Oncogenes in NSCLC — Dr Weiss

• Key efficacy and safety findings with capmatinib or tepotinib for patients with NSCLC with MET exon 14 mutations
• Current role and practical implementation of capmatinib and tepotinib in clinical practice
• Principal efficacy and safety findings with sotorasib for patients with pretreated NSCLC with KRAS G12C mutations; recent FDA accelerated approval and optimal integration into practice
• Recently presented results from the Phase II DESTINY-Lung01 study evaluating trastuzumab deruxtecan (T-DXd) for patients with NSCLC with HER2 mutations
• FDA breakthrough therapy designation for T-DXd and potential nonresearch role for patients with NSCLC with HER2 mutations
• Early data with and ongoing investigations of other novel agents and strategies (eg, telisotuzumab vedotin, datopotamab deruxtecan, seribantumab) for patients with actionable genomic abnormalities

MODULE 5: Current and Future Management of Metastatic NSCLC without a Targetable Tumor Mutation — Dr Langer

• Clinical trial database supporting the FDA approvals of anti-PD-1/PD-L1 antibody monotherapy and combined chemoimmunotherapy for patients with newly diagnosed metastatic NSCLC
• Available results with the use of cemiplimab in combination with platinum-based chemotherapy as up-front therapy for NSCLC
• Long-term follow-up from Phase III trials (CheckMate 227, CheckMate 9LA) evaluating first-line nivolumab/ipilimumab with and without chemotherapy for metastatic NSCLC; optimal integration into practice
• Principal findings from the Phase III POSEIDON trial evaluating first-line durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy
• Biologic rationale for targeting TROP2 in lung cancer; mechanism of action of and available data with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan for patients with progressive metastatic NSCLC
• Other promising agents and strategies (eg, patritumab deruxtecan, plinabulin) for metastatic NSCLC without a targetable tumor mutation

MODULE 6: Current Treatment Paradigm for Small Cell Lung Cancer (SCLC) — Dr Paz-Ares

• Long-term efficacy and safety findings from the Phase III CASPIAN and IMpower133 studies of durvalumab and atezolizumab, respectively, in combination with chemotherapy as first-line treatment for extensive-stage SCLC; factors in selecting a regimen
• Major efficacy and safety findings from key studies (eg, the pivotal Phase II basket trial, ATLANTIS) of lurbinectedin for patients with SCLC who experienced disease progression after prior chemotherapy
• Current clinical role of lurbinectedin for progressive SCLC; ongoing efforts to combine lurbinectedin with other systemic therapies
• Efficacy and safety results from randomized studies evaluating trilaciclib as a means to preserve bone marrow function during chemotherapy in patients with extensive-stage SCLC; recent FDA approval and optimal incorporation of trilaciclib into routine practice
• Other novel agents and strategies under investigation for patients with extensive- or limited-stage SCLC

Thank you for your interest in our CME program taking place in Chicago, IL. At this time ONLINE "IN-PERSON" PREREGISTERATION is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED - ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:00 PM Central Time on Friday, June 3. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (702 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2022 ASCO Annual Meeting website.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Please note, onsite registration does not guarantee meal service which will be based on availability.